Savara Inc
NASDAQ:SVRA

Watchlist Manager
Savara Inc Logo
Savara Inc
NASDAQ:SVRA
Watchlist
Price: 5.64 USD -6.47% Market Closed
Market Cap: 1.1B USD

Savara Inc
Total Receivables

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Savara Inc
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Savara Inc
NASDAQ:SVRA
Total Receivables
$1.1m
CAGR 3-Years
7%
CAGR 5-Years
17%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Total Receivables
$12.8B
CAGR 3-Years
6%
CAGR 5-Years
9%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Total Receivables
$5.1B
CAGR 3-Years
5%
CAGR 5-Years
5%
CAGR 10-Years
-2%
Amgen Inc
NASDAQ:AMGN
Total Receivables
$8.5B
CAGR 3-Years
17%
CAGR 5-Years
16%
CAGR 10-Years
11%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Receivables
$1.9B
CAGR 3-Years
12%
CAGR 5-Years
20%
CAGR 10-Years
28%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Receivables
$5.7B
CAGR 3-Years
1%
CAGR 5-Years
7%
CAGR 10-Years
15%
No Stocks Found

Savara Inc
Glance View

Market Cap
1.1B USD
Industry
Biotechnology

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. The company is headquartered in Austin, Texas and currently employs 22 full-time employees. The company went IPO on 2001-06-25. The firm is focused on rare respiratory diseases. The Company’s lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim an inhaled formulation of recombinant human GM-CSF, is being developed for the treatment of aPAP. Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the build-up of surfactant in the alveoli or air sacs of the lungs.

SVRA Intrinsic Value
2.41 USD
Overvaluation 57%
Intrinsic Value
Price

See Also

What is Savara Inc's Total Receivables?
Total Receivables
1.1m USD

Based on the financial report for Sep 30, 2025, Savara Inc's Total Receivables amounts to 1.1m USD.

What is Savara Inc's Total Receivables growth rate?
Total Receivables CAGR 5Y
17%

Over the last year, the Total Receivables growth was -5%. The average annual Total Receivables growth rates for Savara Inc have been 7% over the past three years , 17% over the past five years .

Back to Top